Studies have showed using TriageHF reduced all-cause hospitalisations by 58% according to Ahmed et al. (2024). Using ...

This page provides a summary of the findings from the report. It includes insight from Kay Boycott, chief executive of the Asthma UK and British Lung Foundation Partnership, about NICE's role in ...

The HTA Lab enables NICE to develop creative solutions to complex problems in health technology assessment. It offers a ‘safe space’ for creating solutions in collaboration with system partners and ...

This page provides a summary of the findings from the report. It includes insight from Dr John Graham, consultant oncologist and cancer lead clinician at Taunton and Somerset NHS Foundation Trust, ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Public involvement is a vital part of the way we work. Our Public Involvement Programme develops and supports the involvement of people who use services, carers and members of the public, along with ...

How has our guidance been used in practice? NICE impact reports review how our guidance is used to improve the health and care of people. We base the reports on data from national audits, reports, ...

Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

This topic was considered by the diagnostics advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in the test to be evaluated. If it ...